Generic Paxil Suicide Lawsuit

Citizens Commission on Human Rights Award Recipient (Twice)
Humanist, humorist

Thursday, May 10, 2018

We Speak For The Dead To Protect The Industry

In 2015 an amendment to the Coroners' Bill was put forward in Ireland on behalf of John and Stephanie McGill Lynch. Their 14-year-old son, Jake (pictured), died after experiencing critical ADR's caused by the SSRI drug Prozac.

Currently, coroners can return an "open verdict" in such deaths. The open verdict means the jury confirms the death is suspicious but sidesteps a definitive verdict. Mr. and Mrs. Lynch wanted this amended to include a new verdict. They proposed the term “iatrogenic suicide” which, in a nutshell, means “the ending of one’s own life where the effect of medical treatment undertaken by the deceased, including any prescribed medication, is the primary cause of such an action."

Yesterday the Irish Times reported on the outcome of Jake’s Amendment.

Minster for Justice Charlie Flanagan ruled out the introduction citing that:
“The proposal from the McGill Lynch family is well-intentioned but cannot be supported. This is mainly because the verdict would apportion some liability on the medical practitioner who may have prescribed the treatment or medication for the deceased person”
I find Flanagan's ruling bizarre and I'm not alone in this assessment. Sinn Féin Senator, Pádraig MacLochlainn, who presented Jake’s Amendment on behalf of the McGill-Lynch family, said it was originally “uncontentious” among all parties in the Seanad but was blocked at the “11th hour.” “My suspicion is that senior medical professionals spooked the minister.”

MacLochlainn makes a valid point. Adding more insult to injury, the Office of the Attorney General advised the proposed verdict would be legally unsound because a new verdict would be capable of ascribing criminal liability to person or persons who are readily identifiable. Unsurprisingly, the Coroners Society of Ireland was opposed to the proposal. It seems the only people the government wants to hold accountable for these avoidable deaths is the victim who died.

The current choice of verdicts open to a coroner or, in legal cases, to a jury, include accidental death; misadventure; suicide; open verdict; natural causes, and; unlawful killing. When a person dies from self-sustained injury, mainstream terminology still labels such deaths as "suicides" despite that many pharma products can and do cause unwanted, ego-dystonic death. Ego-dystonic deaths are "against one's will." That is, if the consumer was not experiencing ADRs caused by pharma products, they would not in their normal undrugged mind, have wanted to die nor died.

Like thousands of other ADR victims, Jake's young mind was chemically abducted by Prozac. Prozac and all SSRIs cause akathisia, psychosis and suicidal thoughts and actions among many unsuspecting consumers. In the US, all SSRIs carry the FDA's most serious Black Box warning stating they can cause life-threatening ADRs. The FDA was forced to include the Black Box warning on SSRIs after thousands of reported deaths and extensive testimony by courageous family members left behind. Unfortunately, the FDA essentially buries the dire warning in tiny print tucked inside a paper envelope most trusting consumers unintentionally discard.

Justice Charlie Flanagan's ruling seems absurd as does his reasoning. Ms. Lynch told the Irish Times she and her husband, from Clondalkin, west Dublin, were “absolutely disgusted, traumatized,” adding that the proposed amendment “would have said ‘without apportioning blame.'" We are not looking for anyone’s head on a plate. But we are looking for some kind of accountability.”

Coroners are first and foremost doctors who sit on the fence regarding prescription drug-induced deaths. Coroners know they can't definitively label any of these deaths "suicides" but they won't protect the public by acknowledging lethal drug effects. If coroners did so, they would then honestly speak for the dead to protect the living. As it stands, coroners continue to deceitfully "speak for the dead" to protect fellow doctors and the drug industry.

The Irish Times article can be read in its entirety here.

Bob Fiddaman


Prozac Took My Child (Guest Post)

Related Website

AntiDepAware ~ Inquest Reports

Monday, May 07, 2018

Titan 1 Jack-In-The-Box 0 - A Tale of Two Attorneys

Last December, I reported on how the legal-based website, Law360, had interviewed King & Spalding's top asshat asset, Andrew Bayman. In the article, Bayman said the Dolin Vs GSK trial, which Bayman lost, was his biggest 'accomplishment.'

Backstories of the trial and Bayman's interview are at the foot of this post.

Yesterday, Law360 flipped the coin and wrote a marvelous piece about one of Dolin's legal counsel, Brent Wisner of Baum Hedlund Aristei & Goldman. The headline reads, "Titan of the Plaintiffs Bar: Baum Hedlund's R. Brent Wisner". Link here (PDF Courtesy of  Baum, Hedlund, Aristei & Goldman)

Fitting that Law360 posted this on May 6 as it marked the 11 year anniversary of the death of 18-year-old Sara Carlin who, like Stewart Dolin, died by "suicide" after being prescribed Paxil (paroxetine)

I covered Sara's inquest on a daily basis and, just as I did for the Dolin trial, reported what mainstream media wouldn't. During Sara's inquest, I frequently spoke with her father, Neil. It was trying times for the Carlin's, more so because drug giant GSK decided to attend the inquest by sending its attorneys.

Fortunately, I was able to attend the Dolin trial and witnessed first-hand the brilliance of Dolin's counsel. Wisner (pictured above) and co-counsel, David Rapoport, carefully crafted and delivered evidence to the jury resulting in a victory for Wendy Dolin, the plaintiff and widow of Stewart Dolin. As Rapoport states in the Law360 article, "His witness examinations were consistently to the point, effective, interesting and often entertaining. He created a David v. Goliath atmosphere that I believe contributed to the plaintiff’s verdict."

I can't top Rapoport's words.

Being present at most of the trial, I witnessed two teams in action. Of course, I had a bias for the plaintiff but tried not to let that influence my reporting. It was interesting to see GlaxoSmithKline's attorneys in action as much as it was Wisner and Rapoport. In fact, I wouldn't be surprised if Andy Bayman required knee surgery after the trial due to constantly springing up from his chair at every given moment shouting 'Objection, your Honor!"

Remarkably, during Bayman's summation, he addressed the jury and rhetorically asked: "Don't you think if these medicines caused suicide someone would have spoken up?"

Unfortunately, the dead cannot speak, but prosecuting attorneys such as Brent "Titan" Wisner can and do speak for the dead. Despite GSK's effort to suppress info via its legal team and paint a false and unfavorable description of Stewart, Wisner introduced the real and likeable Stewart to the jury and the jury didn't buy GSK's attempts to falsely label Stewart as "mentally ill." 

Stewart did speak during the trial and he continues to speak today through the advocacy work of his widow and the caring law firm whose record against GlaxoSmithKline is most admirable. (Law360 also touched on Wisner's work surrounding his involvement in another case, this time against Monsanto Co.)

Law360 also touched on Wisner's work surrounding his involvement in another case, this time against Monsanto Co.

Wisner, Law360 claim, "leaked internal emails from Monsanto to the New York Times which suggested the agrochemical giant may have tried to ghostwrite academic articles exploring, among other things, the health risks of its products. Wisner obtained the documents from the company in a San Francisco federal court case that alleges the company's top-selling weed killer Roundup causes non-Hodgkin's lymphoma."

I have to take my hat off to anyone who leaks drug company internal emails as for too long such emails have been kept hidden from the public.

The success of the Dolin verdict has opened the door for more Paxil lawsuits and this is a positive step for consumers. Brent's employer's, Baum Hedlund, is now investigating more Paxil suicide cases on behalf of families whose loved ones have taken their lives and/or been harmed while on Paxil.

On September 1, 2017, Baum Hedlund sent a letter to Apotex, the current manufacturer of Paxil and paroxetine, putting the company on notice that the Paxil label is inadequate. For a Free Case Evaluation visit here.

With yet another success against GlaxoSmithKline under their belt, Baum Hedlund are now taking on the might of Monsanto.

On December 26, 2015, Californian farmer, Jack McCall passed away after suffering a massive stroke due to complications from a rare version of non-Hodgkin lymphoma. His wife, Teri, has now has filed a wrongful death lawsuit against Monsanto, claiming exposure to Roundup caused her late husband to develop cancer.

More about Jack McCall and further information regarding RoundUp lawsuits can be found here.

This post is dedicated to the memories of Stewart and Sara, both of whom who should be here today, both of whom whose lives tragically ended after taking Paxil.

Nessun dorma.

Bob Fiddaman


Dolin Vs GSK

Dolin v GSK - Opening Arguments

Dolin Vs GSK - Day Two - "Jack-In-The-Box"

Dolin vs GSK - Healy 'Rocks Da House'

Dolin Vs GSK - JP Garnier Video Deposition

Dolin Vs GSK - The Dunbar Tape

Dolin Vs GSK - Day 4 - Slam Dunk

Dolin Vs GSK - 8.9 Suicide Increase For Adult Paxil Users

Dolin Vs GSK - Day 6 - Ass Kicking Semantics

Dolin Vs GSK - Day 7 - Abraham Lincoln

Dolin Vs GSK - Day 8 - Get to the Point, Todd!

Dolin Vs GSK - Glenmullen Nails It!

Dolin Vs GSK - "Babes"

Dolin Vs GSK - Wendy's Cross and GSK's Petition

Dolin Vs GSK - Robert "Bling Bling" Gibbons

Dolin Vs GSK: Suicide Prevention Warning "Futile", Claims GSK Exec

Dolin Vs GSK : Jury shown List of the Dead in Paxil Clinical Trials

Dolin Vs GSK: Last Man Standing & The Return of Dr. Healy

Dolin Vs GSK: Closing Arguments

Sara Carlin

Tuesday, May 01, 2018

Royal College of Psychiatrists Dig Deep Abyss

Back in March, I reported on a letter that was sent to the Royal College of Psychiatrists (RCP) regarding a statement made in The Times newspaper by their two employees, Wendy Burn and David Baldwin.

The statement irked many, myself included, as it was deeply misleading and dangerous. Burn and Baldwin claimed that "We know that in the vast majority of patients, any unpleasant symptoms experienced on discontinuing antidepressants have resolved within two weeks of stopping treatment."

It was James "Scooby" Moore who rumbled the RCP when he confronted Wendy Burn on Twitter shortly after the statement was printed in The Times. You see, the RCP had previously carried out their own study into antidepressant withdrawal and even published the results. It was found that withdrawal symptoms generally lasted for up to 6 weeks. A small percentage of symptoms lasted longer than this. A quarter of the group surveyed by RCP reported anxiety lasting more than 12 weeks.

When Moore pointed this out, the study was removed from the RCP website and RCP claimed they removed it because it "was out of date." ~ Copies of the study were, however, copied by James Moore, you can see the pages here.

On March 9th, 2018, a formal complaint of misleading the public on a matter of public safety was lodged with the RCP against Burn and Baldwin. The complaint was signed by Professor John Read of the University of East London, on behalf of many psychiatrists and victims of antidepressant withdrawal.

Today, John Read and co have published the response from the RCP and it's priceless!

I don't want to spoil your fun by summarizing segments on my blog, you really need to read it in its entirety. (LINK)

If reading isn't your thing then you can listen to a special 9-minute podcast with Professor John Read here. In it, he describes how the RCP are conveniently cherry-picking selective quotes to justify what Burns and Baldwin initially said. It's jaw-dropping!

And I thought the MHRA were the best bricklayers in the UK!

Bob Fiddaman

How it all unfolded

Media Frenzy - Antidepressants Are Safe!

Royal College of Psychiatrists - 63%

Scooby and Those Pesky Tweeters Rumble Psychiatry

Monday, April 23, 2018

Prescribing Death

People who suffer from allergies, medical disorders, and disease usually know best what medications and/or food they can and cannot tolerate.  For example, I suffer from a type of inflammatory arthritis called gout. There are many foods and drinks that my body cannot tolerate. I realize, as do medical specialists, that foods high in purines, such as shellfish, will likely increase the risk that I will suffer a painful gout attack. Therefore, I avoid or reduce my consumption of specific foods and beverages in order to stay healthy.

I'm of sound mind, but if I wasn't, I'd have to rely on my loved ones to ensure foods high in purines are eliminated from my diet. Good health and medical care is often a family affair for all of us, whether we suffer from gout or medication allergies. Most doctors would agree that concerned family members play a vital role in patient care, particularly when the patient is a minor or might need assistance in decision making.

Thomas "Oliver" McGowan (18)

The Poisoning of Oliver McGowan

Eighteen-year-old Thomas Oliver McGowan, known as Oliver, died on November 11, 2016. He lived with cerebral palsy, epilepsy and autism, which began after contracting meningitis twice during childhood. On Saturday, October 22, Oliver was suffering from simple partial seizures and taken by ambulance to Southmead Hospital in Bristol, UK.

Upon arrival, Oliver was intubated, a process of inserting an endotracheal tube through the mouth and into the airway. This was apparently done to place Oliver on a ventilator to assist with his breathing. Oliver was sedated with Lorazepam, a drug indicated to treat seizure disorders. He was then taken for a CT scan which did not show any changes to his brain.

As doctors at Southmead Hospital eased the Lorazepam, Oliver's seizures returned. Instead of reinstating the Lorazepam, the doctors made a decision that ultimately killed Oliver. They prescribed him the antipsychotic, Olanzapine, a drug indicated to treat schizophrenia and bipolar disorder. It is better known in the US by its brand name Zyprexa. Oliver developed Neuroleptic Malignant Syndrome (NMS), an adverse effect of the drug, his temperature rose to 43C and his brain swelled to the point that it was coming out of the base of his skull.

Dr. Monica Mohan

Dr. Monica Mohan's Arrogant Destruction

The consultant neuropsychologist who made the decision to administer Olanzapine is Dr. Monica Mohan. It appears she made a calculation of risks and benefits but ignored more than 500 citations assessing the impact of antipsychotic drugs on challenging behavior. Of these 500 citations, only 3 were methodologically sound randomized controlled trials, and even these were unable to show whether antipsychotic drugs were beneficial in controlling challenging behavior. (1)

Neuropsychology and publications aside, doctors and staff at Southmead Hospital were repeatedly told by both Oliver and his parents, Paula and Tom,  not to give him antipsychotic medications because he was allergic to them.

Oliver's avoidable prescription-drug death and last week's inquest has been covered by the British media. The week-long inquiry showed how doctors, after learning of Oliver's adverse drug reaction to the drug that was administered, performed a CT scan on his brain which showed Oliver’s brain had swelled to the point doctors said there was no “meaningful recovery”.

During the inquiry, consultant neuropsychologist, Dr. Mohan, told the inquest she would do it again because she believed it was in “his (Oliver's ) best interest”.

I kept an eye on the proceedings and, like the majority of the public, I was gobsmacked at last Friday's verdict delivered by Assistant Coroner Dr. Peter Harrowing.

Harrowing, a former Director of Pharmacy Services to the University Hospitals Bristol NHS Foundation Trust, concluded Olanzapine had been properly prescribed and that NMS could not be predicted as it was a “very rare adverse effect”. Further, Harrowing said he agreed with Dr. Mohan. He said the doctors were right to prescribe the drug that precipitated Oliver’s death. Dr. Harrowing also ruled against a Prevention of Future Death.

I reached out to the McGowan family who told me, "The coroner argued that it wasn’t an allergy but a sensitivity or intolerance. Of note, Oliver had previously suffered oculogyric crisis (a dystonic reaction to certain drugs) in Bristol Children’s Hospital with his seizures increasing from one per fortnight to 30 a day.  Sean Collins, safeguarding lead at Southmead Hospital, had consulted with ICU staff about using a non-pharmaceutical approach for when sedation was refused but was not consulted by Mohan."


I'm never shocked anymore by Inquest verdicts. I've long been a fan of the website AntiDepAware, moreover its author Brian. AntiDepAware includes links to reports of inquests held in England and Wales since 2003. It's a great window into the world of coroners and how they don't really work for nor represent the dead. Coroners are often just doctors protecting doctors and the majority repeatedly fail to protect the living by being honest about what happened to the dead. Oliver's case is, tragically, no exception to the medical industry's business-as-usual model. Loved ones who question the medical industry in order to help protect others from suffering avoidable harms are often shocked to see the medical industry's chief concern is to protect their colleagues and business systems.

It's difficult enough to lose a beautiful child who had his whole life ahead of him. But to then endure more smoke-and-mirrors deception from a pharmacist-cum-assistant coroner is beyond the pale. Further, Oliver's parents had to pay for the ordeal following Oliver's death whereas Southmead Hospital was supported throughout the inquest by public funding. (Yes, folks, this is where your hard-earned tax money goes.)

When I think about the avoidable death of the talented and handsome young man named Oliver McGowan, I can't help but also think about thousands of other "Olivers" and "Olivias" out there whose prescribed deaths aren't covered by the news. While they remain faceless to the public, they are not faceless to family and friends.

Nothing will bring Oliver back to life. The inquest that could have reduced future avoidable deaths by improving crisis communication and medical safety instead seem to have increased the likelihood that doctors will practice medicine however they choose, parents be damned.

Arrogance among doctors is a deadly flaw. A 2002 journal article by Allan S. Berger (2) states, "...the most critical variable in the development of arrogance is a physician's knowledge and thereby his or her power over the patient. This can delude some physicians into imagining that they are all-powerful." He continues, "...we should not exaggerate our own importance. We are but an instrument of healing and not its source."

I couldn't agree more.

Bob Fiddaman

(1) Are antipsychotic drugs the right treatment for challenging behaviour in learning disability?: The place of a randomised trial

(2) Arrogance among physicians ~ Berger AS

Thursday, April 19, 2018

Stop It!

Dr. Clare Gerada ~ "Stop it"

Louis Appleby, Government Advisor on the prevention of suicide, opened a can of worms on Twitter last month when he tweeted:

What followed were some jaw-dropping tweets from, Clare Gerada, the person Appleby was promoting.

Who is Clare Gerada?

Clare Gerada is one-half of a psych drug promotion pair. She's married to Simon Wessely, a psychiatrist and professor of psychological medicine at the Institute of Psychiatry, King's College London. Gerada was the chairperson of the Council of the Royal College of General Practitioners from 2010 to 2013. She is also a partner in the Hurley Group which runs a number of GP practices and walk-in centers across London. She was made a Member of the Order of the British Empire in the 2000 Birthday Honours "for service to medicine and to drug misusers"


Now let's take a look at Clare's attempts to stifle conversation about the side effects surrounding 'antidepressants'.

First up to tweet opposition to her views was Australian Army Major Stuart McCarthy. He joined the Australian Army in 1988 and in 1999 deployed to Bougainville, Papua New Guinea where he served as commander of a multi-national patrol in the Peace Monitoring Group.

Towards the end of McCarthy’s Bougainville deployment, he became a subject in an unethical drug trial for the antimalarial drug tafenoquine. In 2001, he spent six months as the deputy force engineer in the United Nations Mission in Ethiopia and Eritrea. While there he was prescribed mefloquine and experienced a variety of adverse drug effects including depression.

Despite recurrent major depression and other debilitating neurological symptoms that he now realises are the result of the undiagnosed neurotoxic brain injury he sustained in 2001, McCarthy served in the Army for 16 additional years.

His full bio is at the foot of this blog post.

McCarthy's April 16th tweet to Gerada asked her three questions. The resulting twitter exchange was priceless despite that Gerada's "responses" were dreadfully predictable.

Click on Twitter images to enlarge.

Undeterred, Major McCarthy pressed Gerada for some answers. Once again, she tried to silence the respected veteran:

I then tweeted Gerada a question asking if she would concede that, for some, they (drugs labeled antidepressants) could be dangerous? Her reply, if you could call it such, was quite puzzling:

So, now she was using her same line on me, Gerada ordered me to "stop it."

Minutes later she made a claim that these drugs save lives and told me to read the 500 clinical trials that prove it. Ahem, I hated to break the following to her:

Gerada could not answer my question because the fact is there have been no clinical trials for drugs labeled antidepressants that supported the claim Gerada made. There are no clinical trials that have found any evidence that taking these drugs saves lives. If there were, pharmaceutical companies would have already printed this bold proclamation on their product packaging. Pharma would never let such a sales and promotional opportunity slip by.

After running face first into a brick wall, Gerada's next tweet was equally lame but more bizarre:

I've previously written about how critics of patient safety advocates throw out the PR stigma line. You can read all about it here.

I then pointed out Gerada's strawman arguments and her shady goal to suppress and shame those harmed by drugs labeled antidepressants. Fiona French, who has been seriously damaged by benzo prescribing, joined the twitter conversation. What is astounding here is the way Gerada diagnoses French.

The conversation seemed to end there, but the following morning Gerada tweeted something even more delusional.

My answer was short and sweet. "Stop it", I said.

Coming late to the twitter round was Kristina Gehrki. Her tweets appeared to have ended Gerada's nonsense. Perhaps Gerada was too busy the last days with her googling "Who is Florence Nightingale?"


Remarkably, just minutes ago, Gerada felt the need to chip in again. This time, responding to a parent whose son died in an 'antidepressant' induced death. Telling a parent whose child died as a result of a prescription that they are 'wrong' is an affront to public health. Her reply also shows an appalling lack of human compassion.

Here's the tweet.

Gerada has now blocked me on Twitter.

Bob Fiddaman

Monday, April 16, 2018

India: GSK Whistleblower Names and Shames - Part II

"This was not just a violation of the standard operating procedures and code of conduct at GSK but also violated several sections of the Constitution of India and Penal Code."

Following on from Part I

In summary, Navneet Kumar, a rep for GSK India, is blowing the whistle on the way the company operates its business out of India.

In Part I, we learned that Kumar was told by senior management to meet his targets by "hook or by crook". Further, Kumar was paying stockists out of his own pocket so senior management would reap the monetary benefits. This despite the GSK rule book stipulating that: "a drug rep should not be involved in any money-related matters with their stockists."

Kumar filed a complaint against his Regional Business Manager, Sanjeev Jolly, who apologized and, well, that was that. GSK officials took no disciplinary action against Jolly.

Part I also highlighted how Kumar's  Area Business Manager (ABM), Jitendra Singh Chauhan (pictured above), would phone him after midnight making demands - he'd even phone Kumar whilst he was on leave. Kumar didn't comply with the demands and was summoned to a meeting at GSK's New Delhi office by Sanjeev Jolly, who asked Kumar to resign. When he refused, Jolly told him, "I will finish your career" and that, "You and your family will be out on the street."

Part II

Because Kumar didn't resign he was issued a charge sheet. It's here that he alleges GSK management created trumped up charges against him because he had brought it to their attention about violations within the company, more specifically his senior management.

Whenever a charge sheet is issued against an employee, that employee has a right to be accompanied by a co-worker or a legal representative. Kumar told me:
"After the charge- sheet was issued, I requested to GSK management to allow me legal representation because of the allegations against me. My request of legal representation was denied by GSK management. So I fought  my case alone  in the enquiry proceedings. The charge sheet alleged they had witnesses but no such witnesses were ever provided by GSK. The enquiry officer was Vipin laroia and from the early stages of the enquiry it appeared he was siding with GSK management."
In fact, according to Kumar, The investigation was trying to hide the witness statements from him. He later learned that the only witnesses GSK had were the two senior managers who had harassed him from the get-go.

Kumar wrote to senior management and asked if they could change the investigating officer, they refused.

Kumar was once again summoned, once again, he was asked to resign, once again, he refused.

Of that meeting Kumar told me:

"Somewhere I noticed that they weren't recording whatever I was saying, which was most disturbed me. Actually, as per the domestic enquiry rules, the job of recorder is to type the ongoing conversation on his laptop, but under the shadow of the enquiry officer and general manager they were acting like that they were typing but at end of enquiry proceedings they only provided me with what management had stated, and not what I had stated. They had also omitted the threats and their calls for me to resign."

Aniruddha Kunte, GSK General Manager -Employee Relations

Kumar, once again, sought help from higher management, this time writing to Aniruddha Kunte, General Manager -Employee Relations.

Kunte told him that after investigating the claims (which surmounted to asking the Inquiry Officers whether or not they were true) he (Kunte) found no evidence that suggested Kumar was being harassed, further, Kumar was told that he should "actively participate in the ongoing Inquiry."

Kumar told me he signed papers under duress as he felt intimated. He wrote, once again to Kunte:

(Email has been altered by me, Bob Fiddaman, for clarity)

Re: The last inquiry session on 10/8/2016 at the Delhi office.

The proceedings of that day were signed by me under duress. Some issues are the same as I told you earlier. But no action was ever taken by you.

The behavior of Mr. Vipin(EO) was the same. He was trying his best to harass me, he is totally under the influence of management.

During the meeting, Mr. Jolly was trying his best to put unnecessary pressure on me. Even when I told him that I was disturbed by his actions he didn't change his behavior and continued to humiliate me.

Therefore, I am requesting you to please make arrangements of a video recording of the Inquiry session.

Navneet Yadav (Kumar)


Kunte never followed up and, more importantly, never provided the video recording to Kumar.

The charges against Kumar stood and at this point, he was joined in 'the field' by his ABM Jitendra Singh Chauhan. Basically, Chauhan would follow Kumar around to see if he was meeting his company objectives, which included meeting doctors and dealers as per company guidelines.

Kumar claims that on day one, Chauhan wasted 2 hours of the day in efforts to make Kumar's daily targets impossible. Kumar also alleges that Chauhan would take company vehicles off other reps which resulted in those reps not being able to meet their targets, he even, at times, according to Kumar, used to demand Kumar's car and bike for personal use. Once again, Kumar brought this to the attention of GSK's employee relations manager, once again, nothing was done.

Chauhan continued to waste time, resulting in Kumar not being able to meet his company objectives. Because of this, and because of the restrictions placed on in, Kumar invited Chauhan to ride with him in the evening - he failed to respond to any of Kumar's text messages suggesting this.

Enter the Handwriting Expert

The charges against Kumar continued, in fact, according to Kumar, he had to endure 10 inquiry sessions. On one such occasion, they accused him of not visiting a doctor that he claimed he had. GSK management claimed that the doctor was out of India at the time so Kumar could not have visited him. Kumar, in his defense, told me:
"I requested that the Inquiry Officer and Management Representative provide evidence in support of their allegation that the doctor was not present in India. After a while they produced a letter purportedly from the doctor. In it, he had written that he was indeed out of the country."
Regarding the apparent letter, Kumar told me:
"I examined that letter very carefully and I realized that it wasn’t written by the doctor. The handwriting matched that of my Area Business Manager, Jitendra Singh Chauhan. I brought this to the attention of the Enquiry Officer who quickly dismissed it."
After this, Kumar acquired the services of a certified handwriting expert who came to the conclusion that the apparent letter from the doctor was, in fact, the same handwriting as Kumar's ABM, Jitendra Singh Chauhan. Armed with this evidence, Kumar showed the Investigating Officer at yet another Inquiry session. He told me:
"In a closed inquiry session room, they abused me and threatened me. I tried to submit my expert handwriting report but they wouldn't accept it from me. Had they accepted it,  they would have seen clearly that Jitendra Singh Chauhan, with the assistance of  Sanjeev Jolly, forged the letter. This was not just a violation of the standard operating procedures and code of conduct at GSK but also violated several sections of the Constitution of India and Penal Code."
Compare two letters and judge for yourself. Were they, as the handwriting expert suggested, both written by the same hand? (Click image to enlarge)

The top is an example of Kumar's Area Business Manager, Jitendra Singh Chauhan, whilst the bottom is, apparently, from the doctor who, it is alleged, was out of the country.

Click Image to Enlarge

Kumar was dismissed from his position at GSK.

Shortly before his dismissal, Kumar sent emails to GSK's Global Head of Investigations, Jason Lord, and GSK's then chief, Andrew Witty. Included in his emails was the handwriting expert report (below) 

Those emails and responses coming up in Part III

Bob Fiddaman

Thursday, April 12, 2018

The Truth About SSRI Withdrawal/Dependence

The following legal brief has rarely been seen by members of the public. Read through it and you'll understand why.

It's a fascinating read and highlights just how GSK hid the withdrawal issues surrounding their popular antidepressant, Paxil.

Many readers will find the following PDF too much to bear. Many will be angered by it, and rightly so. I hope many of you will pass it on to family, friends and even healthcare professionals.

For me, at least, it's the most damning document to ever surface out of litigation. The litigation in question saw GlaxoSmithKline settle with over 3,000 plaintiffs who had struggled to taper off Paxil. Much of the evidence was sealed as part of the 'gagging order' - However, this legal brief gives us an insight into the incestuous relationship between GSK and the FDA. It also shows us how GSK carefully manipulated the system thus putting thousands of future patients through utter misery with debilitating side-effects of withdrawal.

The Yugoslavia trials, mentioned in the document below, are very interesting. Glaxo sponsored the two phases of these trials. In Phase I all patients were given Paxil, in Phase II some were switched to placebo. It was at this stage that the placebo patients began experiencing severe withdrawal issues. Glaxo chose to define this as "relapse" data. This would give them the ammunition to announce later that patients who stayed on Paxil continued to enjoy a normal, "depression free" life, but those abandoning the drug would suffer relapse back into a depressive state.

Back in 2015 I, under the Freedom of Information Act, requested from the MHRA the protocol for this particular clinical trial and whether or not that protocol included information and/or guidance on Paxil withdrawal. The MHRA wrote me and said they "didn't hold that information."

Here's the legal brief.

Bob Fiddaman

Sunday, April 08, 2018

The NYT Addresses Antidepressant Withdrawal Issues

The Lame Defense

You'll hear many lines when discussing the problem of withdrawing from drugs labeled "antidepressants." They include the following:

"These drugs save lives."
"Without them, I wouldn't be here."
"Antidepressants benefit millions of people worldwide."
"They help people get through their daily routine."

While it's not for me to rebut all the above claims, the real issues are that none of the above lines have any relevance into discussing the challenges of "antidepressant" drug withdrawal. Comments such as the above are designed to get people to focus on the purported benefits of "antidepressants" and reduce discussion and/or dismiss discussion about the known risks. These lines are spouted by pharmaceutical companies, pharma-funded "health" and suicide organizations, drug regulators, doctors and consumers of "antidepressants." Some consumers, simply don't care about others who struggle with horrendous and life-threatening adverse drug reactions (ADRs). Perhaps these consumers of "antidepressants" are too frightened to look at the statistics for if they did, many would try to get off these drugs and would then find themselves gaining first-hand experience with SSRI ADRs.

Shifting the blame

If the above illogical responses don't work then the same people use the "shifting the blame" tactic. Some of these tactics include:

"Talk to your doctor."
"You're obviously not ready to come off them yet."
"It's not withdrawal, it's a return of your mental illness."
"Don't believe everything you read on the internet."
"Stop pill-shaming."
"You're a conspiracy theorist."
"Don't you think if these drugs were dangerous someone would have spoken up about them?"

I've heard all these retorts and imagine you've heard some, too. Once again, these retorts are thrown out willy-nilly in an illogical attempt to reduce honest discussion and purposeful action to solve the withdrawal problem caused by drugs labeled "antidepressants." It's an illogical argument and a selfish "I'm alright, Jack" response.

Many people who chant the above retorts state ADRs only happen to a "handful" of people. Even if this were true, how would the claims above help those suffering from severe "antidepressant" ADR's? Does society believe there is a certain magic number of victims that have to be reached before wanting to reduce avoidable suffering? How many people have to die from SSRI ADRs before it is deemed a public health issue worthy of positive action? Are some lives more important than other lives? Considering children and the elderly are two groups most at risk for ADRs, is this a sign our society cares less about children and the elderly?

Do we have to wait until we have inconclusive evidence that shows antidepressants cause severe ADRs in more than half of those who take them?

Time for Broader Discussions

Yesterday, the New York Times published an article entitled, "Many People Taking Antidepressants Discover They Cannot Quit." It's a decent article and the authors, Benedict Carey and Robert Gebeloff, seem to have done their homework with one exception. They stated, "withdrawal has never been a focus of drug-makers or government regulators." This is not accurate and I'll tell you why:

The Yugoslavia Trials 

The Yugoslavia Trials did, indeed, flag the issue of withdrawal surrounding paroxetine (Paxil, Seroxat).

In summary, in 1988 GSK, then SmithKline Beecham (SKB) sponsored clinical trials in Yugoslavia. The purpose of the trials was to show how paroxetine could, when stopped, cause a relapse in depression. SKB never took into account that those relapsing (after stopping paroxetine) could have been suffering withdrawal symptoms.With the results they wanted, SKB then provided the FDA with apparent evidence that showed patients staying on Paxil continued to enjoy a normal, "depression free" life, but that those abandoning the drug would suffer relapse back into a depressive state.

One thing that irked SKB was that they had to convince the FDA that relapses shown in the study were not simply patients suffering withdrawal.
(You can read my coverage of the Yugoslavia trials at the foot of this post.)


Further, back in 2011, the British equivalent of the FDA, the MHRA, launched an "innovative" SSRI Learning Module for prescribing doctors. In it, they stated...
"Symptoms after sudden SSRI discontinuation usually last about one to two weeks and then resolve spontaneously, but they can persist for longer in some patients. Close clinical observation is required to ensure that withdrawal symptoms are not getting worse. Severe cases may call for specialist advice and possible switch to an SSRI with longer half-life before gradual tapering."
I was interested in the "specialist advice" they were recommending to doctors who had patients suffering from worsening withdrawal symptoms. I, therefore, wrote to them and asked for a list of these "specialists." I asked them what training do these specialists have, where do they get this training and by whom?

Despite many weeks of emails back and forth and the usual game of semantics played by the MHRA, they could not provide me with one specialist. The links to the launch of the SSRI Learning Module are below.

Now that is has been more than 7 years since I asked MHRA for a list of specialists and they couldn't list a single one, I pose the question again: Can MHRA provide a list of specialists who are trained to help patients safely withdraw from drugs labeled as "antidepressants."?  I also pose the same question for patients suffering from benzo withdrawal.

The New York Times article is long overdue but I suspect it may well be wrapping up someone's fish & chips tomorrow because that's how this works. Pleas for help go unanswered because the strategy from the psych and pharma industry is to shift blame and change the conversation. They aim to avoid honest discussion of these serious medical issues despite that discussion and awareness would reduce suffering and save lives.

If the Yugolslavia trials don't show you how corrupt this system is, your definition of corrupt is far different than Webster's

Bob Fiddaman

Yugoslavia Trial

The Seroxat/Paxil Yugoslavia Trial Part I

The Seroxat/Paxil Yugoslavia Trial Part II

SSRI Learning Module

MHRA To 'Re-educate' UK Doctor's on SSRi's Part I 

MHRA To 'Re-educate' UK Doctor's on SSRi's Part II "Keeping A Stiff Upper Lip" 

MHRA To 'Re-educate' UK Doctor's on SSRi's Part III - MHRA's Ghosts In The Machine 

MHRA In Buck-Passing Specialist Cahoots 

MHRA - More on the Mysterious "Ghost Specialists" 

MHRA Wishing To Call The Shots

Friday, April 06, 2018

Medicide: What's It All About & What Can We Do?

Natalie Gehrki
Today marks the 12 year anniversary of this blog and with over 2 million views since its conception I find myself posting a recent radio show asking "What can we do?" Over the years I've covered many advocates and their efforts to increase awareness so others might avoid dangerous ineffective drugs. I've covered wrongful death court trials, organizations dedicated to exposing psychiatry and pharma's deceit, tragic losses of life too numerous to count.

Today, I'd like to pose a question to my readers: What can we do? We all have diverse talents, compassion, wisdom that often comes from ADR experiences, and a commitment to positive change. Perhaps there are some great ideas for collaboration out there?

The following interview with Kristina Gehrki went out live on KCAA Radio on Wednesday evening. In it, she explains how she tragically lost her daughter, Natalie (19) to prescription drugs, namely Prozac and Zoloft.

You can download the interview here

Bob Fiddaman

Back Stories

Kidnapped: Natalie’s Story

Kidnapped: Natalie’s Story 2


Let's Bring Akathisia Out of the Darkness

Kristina Gehrki - Twitter

Tuesday, March 27, 2018

India: GSK Whistleblower Names and Shames - Part I

Navneet Kumar started his career with GSK India (Roorkee HQ) on March 2011 where he was assigned to meet doctors on daily a basis to persuade them to prescribe GSK drugs to their patients and to visit other Health Care Professionals (pharmacists, etc.) Kumar also used to organize 'Doctor Roundtable' meetings, and 'Continuing Medical Education' (CME) meetings for GSK product promotions. His job also saw him report to his Area Business Manager (ABM), Mr. Jitendra Singh Chauhan and indirectly to his Regional Business Manager (RBM), Sanjeev Jolly.

Kumar was awarded the 'Super Star' for his excellent sales performance and was given the opportunity to travel to Dubai (paid for by GSK). Many other sales awards were won by Kumar, and all seemed fine with his chosen career at GSK India, that was until he started to notice many irregularities, discrepancies, and became the victim of harassment for not adhering to the unethical sales pressures bestowed upon him by GSK management.

And now, Kumar no longer wants to remain quiet.

Kumar alleges that he and colleagues wrote to GSK Senior Management on the 29th December 2012 about a violation.

Septran (trimethoprim and sulfamethoxazole) is a combination of two antibiotics used to treat ear infections, urinary tract infections, bronchitis, traveler's diarrhea, methicillin-resistant Staphylococcus aureus (MRSA) and Pneumocystis carinii pneumonia. 

On each last working day of the month, Kumar collected orders from stockists. Stockists, according to Kumar, are people who are authorized to buy drugs directly from the company and supply those drugs to chemists or doctors whilst adding their 10% margin.

Kumar told me:

"Stockists buy drugs from the company. Now, let us take an example - GSK's branded drug Septran has a maximum retail price of 100 Rupees. The price to retailers (chemists, etc) costs around 23.5%, around 76 rupees. Now, the same drug will cost stockists 10% less, around 66 rupees because stockists directly buy from the company. 

"Now. it was my manager who was forcing drug reps to do an adjustment. An adjustment is where we have to establish a mutual understanding with stockists. We force them to sell drugs at lower prices like if something is costing them 66 rupees we have to force them to sell the drug on for 60 rupees or even less. This how extra sales will be done. 

"The difference will be paid to stockists by drug reps through their incentive bonus and some part of their salary. This is the cost of staying in the job at GSK.

Managers earn their incentives by threatening the reps. If a drug rep reaches his targets automatically managers will achieve their targets. But the drug rep has to make an adjustment so the money he earns will go to the stockists. Managers earn incentives without any hurdles."

By "hook or by crook"

Kumar alleges that his Regional Business Manager, Sanjeev Jolly (pictured above), told him to reach his sales targets by "hook or by crook". Further, Kumar alleges that Jolly threatened to take action against him if he "didn't do as he was told."

In a nutshell, Kumar tells me, Jolly was telling him to pay his stockist out of his own pocket whilst Jolly reaped the monetary benefits.

According to Kumar, the standard operating procedure at GSK specifies that a drug rep should not be involved in any money-related matters with their stockists.

Other GSK reps have, in the past, received the same kind of threats from Jolly, Kumar and, as a result, saw them write an email to top officials at GSK. According to Kumar GSK's sales reps complained when Jolly instructed them to place an order of 100 cases of Septran tablets.

A grievance meeting was conducted at GSK's New Delhi HQ, Jolly apologized and, well, that was that. GSK officials took no disciplinary action against Jolly.

Jolly's LinkedIn page can be found here - His tagline says that he is an "inquisitive marketeer with an undying thirst to learn and achieve."

According to Kumar, he was the most senior rep but after the grievance meeting against Jolly he was transferred from his hometown to Dehradun (another GSK HQ) in 2015 without any given reason. That's when the harassment started. Kumar told me, "He started harassing me with the help of two Area Business Manager's (ABM), Jitendra Singh Chauhan and Manish Sachdev. They collaborated in handing me a Dealer list on which achieving the company objective was very difficult. Chauhan also sent me unnecessary emails and pressured me to carry out unethical work practices."

This harassment didn't stop at Jolly. Kumar told me that his ABM, Jitendra Singh Chauhan, "...took a massive advantage of his position. He used to send me phone messages at midnight, non-working days and holidays. He used to call me from his home for personal work. When I started objecting to his unnecessary demands, he started taking advantage of his position to harass me even more. He created false allegations against me and started making his own rules whilst overlooking the company guidelines."

Chauhan (Seen below as 'ABM Boss' (1)) told Kumar he wanted him to call 12 dealers per day. The company guideline, however, stipulates that reps will meet no more than 6.5 dealers per day (2)


(see Work Norms/Rules a) and e(i)


"I will finish your career, you and your family will be out on the street."

In effect, Chauhan was almost doubling the workload of Kumar, who believes the unrealistic request to target 12 dealers a day was an effort to get him to resign. I've seen many screenshots of the text messages and, it appears, Chauhan was, in many instances,  sending messages just before and after midnight.

Kumar, despite the demands being put on him, decided to continue working, he would not resign. 

Sometime later, however, he was called into a meeting at GSK's New Delhi office by Sanjeev Jolly. Kumar told me:
"I thought he called me for in for a training program . In a closed room he gave me a white paper and I was asked to submit my resignation. I was shocked and refused to resign. He started threatning me and told me "I will finish your career" and that, "You and your family will be out on the street." He also told me that he will not allow any company to recruit me.
"I was under immense pressure to resign but I didn't. I asked him to provide reasons for why he is doing all these things. Then he presented a charge-sheet in front of me and, once again, asked me to resign. I decided to go with the charge-sheet rather than resignation. He (Jolly) did the same thing with my ex-colleague some months previously, he, like me, was called to the New Delhi office, and under pressure from Jolly, he resigned. This a pattern by GSK management to threaten the employee and they usually resign because the pressure is overwhelming for them. I didn't do that."

Coming up in Part II

  • How Navneet alleges that there is no code of conduct amongst GSK India's senior management
  • More evidence of retaliation and harassment
  • Alleged forgery by GSK management
  • Emails to former GSK CEO, Andrew Witty, GSK's Global Head of Investigation, Jason Lord, and current CEO, Emma Walmsley, and some other top officials of GSK
  • For the first time, Kumar will reveal a document that, so far, has been unseen by the public.

Bob Fiddaman

Back story - Truthman Blog

Please contact me if you would like a guest post considered for publication on my blog.